Immunotherapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapy stocks.

Immunotherapy Stocks Recent News

Date Stock Title
May 16 DTIL Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)
May 16 FBIO Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
May 16 FBIO Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 15 FBIO Fortress Biotech GAAP EPS of -$1.03 beats by $0.70, revenue of $13M misses by $1.13M
May 15 FBIO Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 15 FBIO Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 15 FBIO AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
May 15 FBIO Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 15 ABOS Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
May 15 ABOS Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
May 14 ABOS Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
May 14 PYXS Pyxis Oncology GAAP EPS of -$0.06, revenue of $16.1M
May 14 FBIO Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
May 14 PYXS Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
May 14 IMTX Immatics reports Q1 results
May 14 ABOS Acumen Pharmaceuticals GAAP EPS of -$0.25
May 14 ABOS Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 14 IMTX Immatics Announces First Quarter 2024 Financial Results and Business Update
May 13 CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
May 13 FBIO Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Immunotherapy

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags